TherapeuticsMD, Inc. — Director's Dealing 2015

May 22, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2015-05-20

Reporting Person: Krassan Mitchell (EVP, Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-20	Common Stock	M	60000	$0.1874	Acquired	60000	Direct
2015-05-20	Common Stock	S	60000	$6.5559	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-05-20	Non-Qualified Stock Option (right to buy)	$0.1874	M	60000	Disposed	2020-05-01	Common Stock (60000)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.63 to $6.50, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.